I 
113TH CONGRESS 
2D SESSION 
H. R. 4771 
To amend the Controlled Substances Act to more effectively regulate anabolic 
steroids. 
IN THE HOUSE OF REPRESENTATIVES 
MAY 29, 2014 
Mr. PITTS (for himself and Mr. PALLONE) introduced the following bill; which 
was referred to the Committee on Energy and Commerce, and in addition 
to the Committee on the Judiciary, for a period to be subsequently deter-
mined by the Speaker, in each case for consideration of such provisions 
as fall within the jurisdiction of the committee concerned 
A BILL 
To amend the Controlled Substances Act to more effectively 
regulate anabolic steroids. 
Be it enacted by the Senate and House of Representa-
tives of the United States of America in Congress assembled, 
SECTION 1. SHORT TITLE. 
This Act may be cited as the ‘‘Designer Anabolic 
Steroid Control Act of 2014’’. 
SEC. 2. AMENDMENTS TO THE CONTROLLED SUBSTANCES 
ACT. 
(a) DEFINITIONS.—Section 102(41) of the Controlled 
Substances Act (21 U.S.C. 802(41)) is amended— 
VerDate Mar 15 2010 
00:23 Jun 05, 2014
Jkt 039200
PO 00000
Frm 00001
Fmt 6652
Sfmt 6201
E:\BILLS\H4771.IH
H4771
rfrederick on DSK6VPTVN1PROD with BILLS
(1) in subparagraph (A)— 
(A) in clause (xlix), by striking ‘‘and’’ at 
the end; 
(B) by redesignating clause (xlx) as clause 
(lxxvii); and 
(C) by inserting after clause (xlix) the fol-
lowing: 
‘‘(l) 5α-Androstan-3,6,17-trione; 
‘‘(li) Androst-4-ene-3,6,17-trione; 
‘‘(lii) 
Androsta-1,4,6-triene-3,17- 
dione; 
‘‘(liii) 6-bromo-androstan-3,17-dione; 
‘‘(liv) 
6-bromo-androsta-1,4-diene- 
3,17-dione; 
‘‘(lv) 
4-chloro-17α-methyl-androsta- 
1,4-diene-3,17β-diol; 
‘‘(lvi) 4-chloro-17α-methyl-androst-4- 
ene-3β,17β-diol; 
‘‘(lvii) 
4-chloro-17α-methyl-17β-hy-
droxy-androst-4-en-3-one; 
‘‘(lviii) 
4-chloro-17α-methyl-17β-hy-
droxy-androst-4-ene-3,11-dione; 
‘‘(lix) 
4-chloro-17α-methyl-androsta- 
1,4-diene-3,17β-diol; 
VerDate Mar 15 2010 
00:23 Jun 05, 2014
Jkt 039200
PO 00000
Frm 00002
Fmt 6652
Sfmt 6201
E:\BILLS\H4771.IH
H4771
rfrederick on DSK6VPTVN1PROD with BILLS
‘‘(lx) 
2α,17α-dimethyl-17β-hydroxy- 
5α-androstan-3-one; 
‘‘(lxi) 
2α,17α-dimethyl-17β-hydroxy- 
5β-androstan-3-one; 
‘‘(lxii) 
2α,3α-epithio-17α-methyl-5α- 
androstan-17β-ol; 
‘‘(lxiii) [3,2-c]-furazan-5α-androstan- 
17β-ol; 
‘‘(lxiv) 3β-hydroxy-estra-4,9,11-trien- 
17-one; 
‘‘(lxv) 
17α-methyl-androst-2-ene- 
3,17β-diol; 
‘‘(lxvi) 17α-methyl-androsta-1,4-diene- 
3,17β-diol; 
‘‘(lxvii) Estra-4,9,11-triene-3,17-dione; 
‘‘(lxviii) 
18a-Homo-3-hydroxy-estra- 
2,5(10)-dien-17-one; 
‘‘(lxix) 6α-Methyl-androst-4-ene-3,17- 
dione; 
‘‘(lxx) 
17α-Methyl-androstan-3- 
hydroxyimine-17β-ol; 
‘‘(lxxi) 17α-Methyl-5α-androstan-17β- 
ol; 
‘‘(lxxii) 17β-Hydroxy-androstano[2,3- 
d]isoxazole; 
VerDate Mar 15 2010 
00:23 Jun 05, 2014
Jkt 039200
PO 00000
Frm 00003
Fmt 6652
Sfmt 6201
E:\BILLS\H4771.IH
H4771
rfrederick on DSK6VPTVN1PROD with BILLS
‘‘(lxxiii) 17β-Hydroxy-androstano[3,2- 
c]isoxazole; 
‘‘(lxxiv) 
4-Hydroxy-androst-4-ene- 
3,17-dione[3,2-c]pyrazole-5α-androstan- 
17β-ol; 
‘‘(lxxv) 
[3,2-c]pyrazole-androst-4-en- 
17β-ol; 
‘‘(lxxvi) [3,2-c]pyrazole-5α-androstan- 
17β-ol; and’’; and 
(2) by adding at the end the following: 
‘‘(C)(i) Subject to clause (ii) and the limi-
tations under section 201(i)(6), a drug or hor-
monal 
substance 
(other 
than 
estrogens, 
progestins, corticosteroids, and dehydroepian-
drosterone) that is not listed in subparagraph 
(A) and is derived from, or has a chemical 
structure substantially similar to, 1 or more an-
abolic steroids listed in subparagraph (A) shall 
be considered to be an anabolic steroid for pur-
poses of this Act if— 
‘‘(I) the drug or substance has been 
created or manufactured with the intent of 
producing a drug or other substance that 
either— 
‘‘(aa) promotes muscle growth; or 
VerDate Mar 15 2010 
00:23 Jun 05, 2014
Jkt 039200
PO 00000
Frm 00004
Fmt 6652
Sfmt 6201
E:\BILLS\H4771.IH
H4771
rfrederick on DSK6VPTVN1PROD with BILLS
‘‘(bb) otherwise causes a pharma-
cological effect similar to that of tes-
tosterone; or 
‘‘(II) the drug or substance has been, 
or is intended to be, marketed or otherwise 
promoted in any manner suggesting that 
consuming it will promote muscle growth 
or any other pharmacological effect similar 
to that of testosterone. 
‘‘(ii) A substance shall not be considered to 
be a drug or hormonal substance for purposes 
of this subparagraph if it— 
‘‘(I) is— 
‘‘(aa) an herb or other botanical; 
‘‘(bb) a concentrate, metabolite, 
or extract of, or a constituent isolated 
directly from, an herb or other botan-
ical; or 
‘‘(cc) a combination of 2 or more 
substances described in item (aa) or 
(bb); and 
‘‘(II) is a dietary ingredient for pur-
poses of the Federal Food, Drug, and Cos-
metic Act (21 U.S.C. 301 et seq.). 
VerDate Mar 15 2010 
00:23 Jun 05, 2014
Jkt 039200
PO 00000
Frm 00005
Fmt 6652
Sfmt 6201
E:\BILLS\H4771.IH
H4771
rfrederick on DSK6VPTVN1PROD with BILLS
‘‘(iii) In accordance with section 515(a), 
any person claiming the benefit of an exemption 
or exception under clause (ii) shall bear the 
burden of going forward with the evidence with 
respect to such exemption or exception.’’. 
(b) CLASSIFICATION AUTHORITY.—Section 201 of 
the Controlled Substances Act (21 U.S.C. 811) is amend-
ed by adding at the end the following: 
‘‘(i) TEMPORARY AND PERMANENT SCHEDULING OF 
RECENTLY EMERGED ANABOLIC STEROIDS.— 
‘‘(1) The Attorney General may issue a tem-
porary order adding a drug or other substance to 
the list of anabolic steroids if the Attorney General 
finds that— 
‘‘(A) the drug or other substance satisfies 
the criteria for being considered an anabolic 
steroid under section 102(41) but is not listed 
in that section or by regulation of the Attorney 
General as being an anabolic steroid; and 
‘‘(B) adding such drug or other substance 
to the list of anabolic steroids will assist in pre-
venting the unlawful importation, manufacture, 
distribution, or dispensing of such drug or other 
substance. 
VerDate Mar 15 2010 
00:23 Jun 05, 2014
Jkt 039200
PO 00000
Frm 00006
Fmt 6652
Sfmt 6201
E:\BILLS\H4771.IH
H4771
rfrederick on DSK6VPTVN1PROD with BILLS
‘‘(2) An order issued under paragraph (1) shall 
not take effect until 30 days after the date of the 
publication by the Attorney General of a notice in 
the Federal Register of the intention to issue such 
order and the grounds upon which such order is to 
be issued. The order shall expire not later than 24 
months after the date it becomes effective, except 
that the Attorney General may, during the pendency 
of proceedings under paragraph (5), extend the tem-
porary scheduling order for up to 6 months. 
‘‘(3) A temporary scheduling order issued under 
paragraph (1) shall be vacated upon the issuance of 
a permanent scheduling order under paragraph (5). 
‘‘(4) An order issued under paragraph (1) is 
not subject to judicial review. 
‘‘(5) The Attorney General may, by rule, issue 
a permanent order adding a drug or other substance 
to the list of anabolic steroids if such drug or other 
substance satisfies the criteria for being considered 
an anabolic steroid under section 102(41). Such 
rulemaking may be commenced simultaneously with 
the issuance of the temporary order issued under 
paragraph (1).’’. 
(c) LABELING REQUIREMENTS.— 
VerDate Mar 15 2010 
00:23 Jun 05, 2014
Jkt 039200
PO 00000
Frm 00007
Fmt 6652
Sfmt 6201
E:\BILLS\H4771.IH
H4771
rfrederick on DSK6VPTVN1PROD with BILLS
(1) IN GENERAL.—The Controlled Substances 
Act is amended by inserting after section 305 (21 
U.S.C. 825) the following: 
‘‘SEC. 305A. OFFENSES INVOLVING FALSE LABELING OF AN-
ABOLIC STEROIDS. 
‘‘(a) UNLAWFUL ACTS.— 
‘‘(1) It shall be unlawful— 
‘‘(A) to import into the United States or to 
export from the United States; 
‘‘(B) to manufacture, distribute, dispense, 
sell, or offer to sell; or 
‘‘(C) to possess with intent to manufac-
ture, distribute, dispense, sell, or offer to sell; 
any anabolic steroid, or any product containing an 
anabolic steroid, unless it bears a label clearly identi-
fying any anabolic steroid contained in such steroid 
or product by the nomenclature used by the Inter-
national Union of Pure and Applied Chemistry 
(IUPAC). 
‘‘(2) A product that is the subject of an ap-
proved application as described in section 505(b), (i) 
or (j) of the Federal Food, Drug, and Cosmetic Act 
(21 U.S.C. 355(b), (i), or (j)) is exempt from the 
International Union of Pure and Applied Chemistry 
nomenclature requirement of this subsection if such 
VerDate Mar 15 2010 
00:23 Jun 05, 2014
Jkt 039200
PO 00000
Frm 00008
Fmt 6652
Sfmt 6201
E:\BILLS\H4771.IH
H4771
rfrederick on DSK6VPTVN1PROD with BILLS
product is labeled in the manner required by the 
Federal Food, Drug, and Cosmetic Act. 
‘‘(b) CRIMINAL PENALTIES.—Any person who vio-
lates subsection (a) knowing, intending, or having reason-
able cause to believe, that the substance or product is an 
anabolic steroid, or contains an anabolic steroid, shall be 
sentenced to a term of imprisonment of not more than 
10 years, a fine not to exceed the greater of that author-
ized in accordance with the provisions of title 18, United 
States Code, or $500,000 if the defendant is an individual 
or $2,500,000 if the defendant is other than an individual, 
or both. 
‘‘(c) CIVIL PENALTIES.— 
‘‘(1) Any person who violates subsection (a) 
shall be subject to a civil penalty as follows: 
‘‘(A) In the case of an importer, exporter, 
manufacturer, or distributor (other than as pro-
vided in subparagraph (B)), up to $500,000 per 
violation. For purposes of this subparagraph, a 
violation is defined as each instance of importa-
tion, exportation, manufacturing, or distribu-
tion, and each anabolic steroid or product im-
ported, exported, manufactured, or distributed. 
‘‘(B) In the case of a sale or offer to sell 
at retail, up to $25,000 per violation. For pur-
VerDate Mar 15 2010 
00:23 Jun 05, 2014
Jkt 039200
PO 00000
Frm 00009
Fmt 6652
Sfmt 6201
E:\BILLS\H4771.IH
H4771
rfrederick on DSK6VPTVN1PROD with BILLS
poses of this subparagraph, each sale and each 
product offered for sale shall be considered a 
separate violation. Continued offers to sell by a 
person 10 or more days after written notice (in-
cluding through electronic message) to the per-
son by the Attorney General or the Secretary 
shall be considered additional violations. 
‘‘(2) In this subsection, the term ‘product’ 
means a discrete article, either in bulk or in finished 
form prepared for sale. A number of articles, if simi-
larly packaged and bearing identical labels, shall be 
considered as one product, but each package size, 
form, or differently labeled article shall be consid-
ered a separate product. 
‘‘(d) IDENTIFICATION AND PUBLICATION OF LIST OF 
PRODUCTS CONTAINING ANABOLIC STEROIDS.— 
‘‘(1) The Attorney General may, in his discre-
tion, collect data and analyze products to determine 
whether they contain anabolic steroids and are prop-
erly labeled in accordance with this section. The At-
torney General may publish in the Federal Register 
or on the website of the Drug Enforcement Adminis-
tration a list of products that he has determined, 
based on substantial evidence, contain an anabolic 
VerDate Mar 15 2010 
00:23 Jun 05, 2014
Jkt 039200
PO 00000
Frm 00010
Fmt 6652
Sfmt 6201
E:\BILLS\H4771.IH
H4771
rfrederick on DSK6VPTVN1PROD with BILLS
steroid and are not labeled in accordance with this 
section. 
‘‘(2) The absence of a product from the list re-
ferred to in paragraph (1) shall not constitute evi-
dence that the product does not contain an anabolic 
steroid.’’. 
(2) TABLE OF CONTENTS.—The table of con-
tents for the Comprehensive Drug Abuse Prevention 
and Control Act of 1970 is amended by inserting 
after the item relating to section 305 the following: 
‘‘Sec. 305A. Offenses involving false labeling of anabolic steroids.’’. 
Æ 
VerDate Mar 15 2010 
00:23 Jun 05, 2014
Jkt 039200
PO 00000
Frm 00011
Fmt 6652
Sfmt 6301
E:\BILLS\H4771.IH
H4771
rfrederick on DSK6VPTVN1PROD with BILLS